首页> 外文期刊>Trials >Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial
【24h】

Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial

机译:简化务实随机临床试验中的机构审查委员会进程:从阿司匹林给药中吸取的挑战和经验教训:以患者为中心的试验评估益处和长期有效性(适应)审判

获取原文
       

摘要

Background New considerations during the ethical review processes may emerge from innovative, yet unfamiliar operational methods enabled in pragmatic randomized controlled trials (RCT), potentially making institutional review board (IRB) evaluation more complex. In this manuscript, key components of the pragmatic “Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE)” randomized trial that required a reappraisal of the IRB submission, review, and approval processes are discussed. Main text ADAPTABLE is a pragmatic, multicenter, open-label RCT evaluating the comparative effectiveness of two doses of aspirin widely used for secondary prevention (81?mg and 325?mg) in 15,000 patients with an established history of atherosclerotic cardiovascular disease. The electronic informed consent form is completed online by the participants at the time of enrollment, and endpoint ascertainment is conducted through queries of electronic health records. IRB challenges encountered regarding centralized IRB evaluation, electronic informed consent, patient engagement, and risk determination in ADAPTABLE are described in this manuscript. The experience of ADAPTABLE encapsulates how pragmatic protocol components intended to facilitate the study conduct have been tempered by unexpected, yet justified concerns raised by local IRBs. How the lessons learned can be applied to future similar pragmatic trials is delineated. Conclusion Development of engaging communication channels between IRB and study personnel in pragmatic randomized trials as early as at the time of protocol design allows to reduce issues with IRB approval. Integrations of the lessons learned in ADAPTABLE regarding the IRB process for centralized IRBs, informed consent, patient engagement, and risk determination can be emulated and will be instrumental in future pragmatic studies.
机译:背景技术伦理审查过程中的新考虑因素可能出现在务实的随机对照试验(RCT)中启用了创新,但不熟悉的操作方法,可能使机构审查委员会(IRB)评估更加复杂。在本手稿中,务实的“阿司匹林给药”的关键组成部分:患者以患者为中心的试验评估益处和长期有效性(适应)的随机试验,要求重新评估IRB提交,审查和审批程序。主要文本适应是一种务实的多中心,开放标签RCT评估两种剂量的阿司匹林广泛用于二次预防(81×mg和325μm)的比较有效性,在15,000名患有动脉粥样硬化血管病历史的历史历史中。电子知情同意书在注册时的参与者在线完成,并通过电子健康记录查询进行终点确定。在本手稿中描述了关于集中式IRB评估,电子知情同意,患者参与和适应症的风险确定的IRB挑战。适应性的经验封装了促进研究行为的务实协议组成部分是通过意外的繁殖的,但当地IRB提出的令人担忧的担忧。如何应用于未来类似的务实试验的经验教训是划定的。结论在协议设计时,务实随机试验中的IRB与学习人员之间的参与沟通渠道的开发允许减少IRB批准的问题。可以刺激对集中式IRB,知情同意,患者参与和风险决定的适应性的经验教训的集成,并将在未来的务实研究中有用。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号